The Familial Amyloid Neuropathies drugs in development market research report provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Familial Amyloid Neuropathies. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Familial Amyloid Neuropathies by eight companies/universities/institutes. The top development phase for Familial Amyloid Neuropathies is phase ii with three drugs in that stage. The Familial Amyloid Neuropathies pipeline has six drugs in development by companies and two by universities/ institutes. Some of the companies in the Familial Amyloid Neuropathies pipeline products market are: IRCCS Policlinico San Matteo, Mitsubishi Tanabe Pharma and University of California Los Angeles.
The key targets in the Familial Amyloid Neuropathies pipeline products market include Transthyretin, Microtubule Associated Protein Tau, and Phosphate.
The key mechanisms of action in the Familial Amyloid Neuropathies pipeline product include Transthyretin Inhibitor with six drugs in Pre-Registration. The Familial Amyloid Neuropathies pipeline products include five routes of administration with the top ROA being Intravenous and five key molecule types in the Familial Amyloid Neuropathies pipeline products market including Small Molecule, and Gene Therapy.
Familial Amyloid Neuropathies overview
Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness, and fainting. Supportive treatment includes diuretics, calcium channel blockers, beta blockers, angiotensin receptor blockers, and angiotensin converting enzyme (ACE) inhibitors.
For a complete picture of Familial Amyloid Neuropathies’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
